Human bocavirus: As an emerging respiratory pathogen.

Abstract

Acute respiratory infections (ARIs) are the main cause of morbidity and mortality worldwide, especially among children. The human bocavirus (HBoV) is a non-enveloped DNA virus that was recently identified as a respiratory pathogen associated with respiratory tract infections (RTIs), predominantly in infants and young children. It is also detected from the gastrointestinal tract in children. The prevalence of HBoV1 acute respiratory tract infection varies across age groups, ranging from 10.3% to 12.51% in individuals under 3 years of age. The spectrum of clinical presentation includes mild upper RTIs, acute exacerbation of asthma, bronchitis, bronchiolitis, pneumonia, and multi-organ failure. Although HBoV is often detected in patients with ARIs who have other respiratory viruses (17%-85%), recent studies have identified it as the sole aetiology for mild to severe ARIs. Children with pre-existing medical conditions infected with HBoV often have a risk of severe illness. HBoV infection is diagnosed primarily by detecting viral DNA in respiratory samples using molecular methods. Currently, there is no specific antiviral treatment for HBoV infections and the cases are managed symptomatically. General preventive measures used for the prevention of viral RTIs are applicable, as there is no effective vaccine against this virus. The HBoV has been implicated in RTIs, particularly in children, and has also been detected in cases of gastroenteritis. Despite its global prevalence, the exact pathogenic role of HBoV remains unclear due to frequent co-infections with other viruses. This mini-review discusses the virology, epidemiology, clinical manifestations, diagnosis, and potential treatment approaches related to HBoV infections.